TOKYO and XIAMEN, China, March 27, 2023 Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. today announced that the Japanese Ministry of Health, Labour. | March 27, 2023
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer PREMIA Holdings (HK) Ltd. Hong Kong, HONG KONG
TOKYO and XIAMEN, China, June 30, 2021 (GLOBE NEWSWIRE) Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx
® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on June 25, 2021.